Updated restrictions for Gilenya: multiple sclerosis medicine not to be used in pregnancy
Press release
Human
Medicines
EMA has recommended that the multiple sclerosis medicine Gilenya (fingolimod) must not be used in pregnant women and in women able to have children who are not using effective contraception. If a woman becomes pregnant while using Gilenya, the medicine must be stopped and the pregnancy will have to be closely monitored. This is because the active substance in Gilenya, fingolimod, can harm the unborn baby and may cause birth defects.
To minimise this risk, women able to have children must have a pregnancy test before starting treatment with Gilenya to ensure they are not pregnant, and must use effective contraception during treatment and for two months after stopping the medicine.
These recommendations follow a review triggered by reports suggesting that the risk of birth defects in infants who have been exposed to Gilenya during pregnancy is twice as high as the 2 to 3% risk observed in the general population. The most frequently reported birth defects in infants exposed to Gilenya were those affecting the heart, kidneys, bones and muscles.
Doctors, patients and carers will receive updated educational materials with information about this risk and what actions and precautions need to be taken to ensure the safe use of Gilenya.
These updated recommendations follow a review of available data triggered by post-marketing reports suggesting that infants born to mothers treated with fingolimod during pregnancy have a two-fold increased risk of major congenital malformations compared with the rate observed in the general population (which is 2-3 %, according to EUROCAT - the European network of population-based registries for the epidemiological surveillance of congenital anomalies1.
The most frequently reported major malformations in infants exposed to fingolimod in utero are congenital heart diseases (such as atrial and ventricular septal defects, tetralogy of Fallot), renal abnormalities and musculoskeletal abnormalities.
Updated educational materials to help counsel patients about the risk of reproductive toxicity will be made available and will include a physician’s checklist, a guide for patients, parents and caregivers and a pregnancy-specific patient reminder card.
Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease in which inflammation destroys the protective sheath surrounding the nerve cells. ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly. Gilenya contains the active substance fingolimod.
More information on Gilenya can be found on the EMA website.
The review of Gilenya was conducted by EMA’s safety committee (PRAC) and its human medicines committee (CHMP) in the context of a procedure known as a ‘type II variation’.
The European Commission will issue a legally binding decision valid throughout the EU in due course.